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Abstract  
Background 
The optimal prognostic factors in patients with advanced cancer are not known as a 
comparison of these is lacking. The aim of the present study was to determine the optimal 
prognostic factors by comparing the most validated factors.  
Materials and Methods  
A multicentre, prospective observational cohort study recruited patients over 18 years with 
advanced cancer. The following were assessed: clinician predicted survival (CPS), Eastern 
Cooperative Oncology Group performance status (ECOG – PS), patient reported outcome 
measures (anorexia, cognitive impairment, dyspnoea, global health), metastatic disease, 
weight loss, modified Glasgow Prognostic Score (mGPS) based on C-reactive protein (CRP) 
and albumin, lactate dehydrogenase (LDH), and white (WCC), neutrophil (NC) and 
lymphocyte (LCC) cell counts. Survival at one and three months was assessed using area 
under the receiver operating curve (AUC) and logistic regression analysis.  
Results 
Data were available on 478 patients and the median (IQR) survival was 4.27 (1.86-7.03) 
months. On univariate analysis, the following factors predicted death at one and three 
months: CPS, ECOG-PS, mGPS, WCC, NC (all p<0.001), dyspnoea, global health (both 
p<0.001), cognitive impairment, anorexia, LDH (all p<0.01) and weight loss (p<0.05). On 
multivariate analysis ECOG-PS, mGPS and NC were independent predictors of survival at 
one and three months (all p<0.01).  
Conclusions 
The simple combination of ECOG-PS and mGPS is an important novel prognostic 
framework which can alert clinicians to patients with good performance status who are at 
increased risk of having a higher symptom burden and dying at 3 months.  From the recent 
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literature it is likely that this framework will also be useful in referral for early palliative care 
with 6-24 months survival. 
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Implications for practice.  
 This large cohort study examined all validated prognostic factors in a head-to-head 
comparison and demonstrate the superior prognostic value of the ECOG-PS/mGPS 
combination over other prognostic factors. 
 This combination is simple, accurate and also relates to quality of life. It may be 
useful in identifying patients who may benefit from early referral to palliative care.  
 We propose ECOG-Performance Status/mGPS as the new prognostic domain in 
patients with advanced cancer. 
Gap between current and best practice 
 ECOG-PS is currently used as the main prognostic marker however it can be 
challenging to accurately assess and is subjective.  
 The systemic inflammatory response as measured by the modified Glasgow 
Prognostic Score (mGPS), has been extensively reported and is comparable to PS in 
terms of prognostic accuracy; however the mGPS is entirely objective.  
 The best practice in prognostication would be to use the combination of ECOG-
PS/mGPS which improves survival prediction of either in isolation. 
 
Learning Objectives 
BEST PRACTICE CURRENT 
PRACTICE 
RESULTING GAPS LEARNING 
OBJECTIVES 
ECOG-PS and mGPS 
in combination work 
better than either in 
isolation and reliably 
predicts survival in 
patients with 
advanced cancer. 
ECOG-PS is the 
main prognostic 
marker used in 
patients with 
advanced cancer.  
The use of the 
ECOG-PS/ mGPS 
framework requires 
to be evaluated in the 
context of 
randomised 
controlled trials in 
clinical oncology. 
To understand that 
various clinic-
pathological factors 
are prognostic.  
To understand that 
the ECOG-PS/mGPS 
framework reliably 
predicts survival in 
patients with 
advanced cancer. 
To be aware that 
ECOG-PS/mGPS 
framework relates to 
quality of life.  
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Background 
“How long have I got?”  
This is often the first question patients ask when they are told that their cancer is 
incurable. Most clinicians find this challenging to answer but rely on their experience, 
clinical intuition and the possible outcome of therapies, when considering their answer. Of 
course, some patients may not want to know their likely outcome. Either way, it is important 
that the clinician has an awareness of the likely survival as this will inform important 
decisions around appropriateness of anti-cancer therapy[1, 2] and  place of care.[3] It may 
also relieve patient and family anxiety associated with prognostic uncertainty.[3] 
In patients with advanced cancer,  measures of performance status  (e.g. Eastern 
Cooperative Oncology Group Performance Status  [ECOG-PS]) remain the most reliable 
prognostic factor. These are widely used in oncology practice to help inform important 
decisions but have been criticised as being subjective, inaccurate and overly optimistic. [4]  
  Since 2005, there has been a clear drive to try and augment prognostic accuracy with 
several clinical and bio-markers being identified as having prognostic value.[5-7]  Clinical 
markers with prognostic value include anorexia, cognitive impairment, dyspnoea, global 
health and weight loss in the last 3 months.[5, 8] Bio-markers include lactate dehydrogenase 
(LDH), and white (WCC), neutrophil (NC) and lymphocyte (LC) cell counts, and the 
modified Glasgow Prognostic Score (mGPS – a combination of C-reactive protein [CRP] and 
Albumin). The mGPS measures the inflammatory response and has demonstrated the role of 
the host-tumour inflammatory response in prognosis[9] in addition to its established role in 
tumour genesis and quality of life.[10, 11]  
Although such factors have been identified and advocated, it is not clear which factors 
are optimal since a comparison has not, to date, been done. Despite the time invested in 
advancing the research agenda in prognosis, it is not clear what  the optimal prognostic 
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factors are as a prospective comparison has not been done. In particular, it is not known how 
established prognostic markers such as performance status compare to newer clinical and bio-
markers. Therefore, the aim of the present study was to compare prospectively, validated 
prognostic factors in a cohort of patients with advanced cancer.   
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Methods 
Study Population 
Adult patients (> 18 years) were recruited from either one of nine regional cancer 
centre’s or one of seven specialist palliative care units in the UK (listed in 
acknowledgements).  Patients had cancer which was defined as incurable. This encompassed 
metastatic cancer [histological, cytological or radiological evidence], non-disseminated 
cancer (e.g. glioblastoma multiforme), locally advanced cancer (e.g. pancreatic cancer) or 
haematological malignancies who were being treated/previously been treated with anti-cancer 
therapy with palliative intent. Eligible patients also were able to complete study 
questionnaires; provide a venous blood sample; performance status of 1-4 (ECOG) as agreed 
by their treating clinician. Patients were excluded if they had breast or prostate carcinoma 
with only bone metastases, as in some cases their survival may be many years.  Patients were 
either inpatients or outpatients, undergoing anti-cancer therapy or not. Adjustments were 
made for age, sex and having lung, gastrointestinal or other cancers and the analysis adjusted 
accordingly. There were no protocol modifications. The study had ethics committee approval 
(UK – 12/SS/0181) and was conducted in accordance with the Declaration of Helsinki. All 
patients provided written informed consent. The study adhered to the STROBE guidelines for 
cohort studies. 
Centres were opened on a staggered basis. At each centre, consecutive patients who 
met the eligibility criteria were invited to participate (sequential sampling) and consented, 
reducing selection bias. All assessments, including blood sampling, were done on the day of 
consent. 
 
Prognostic markers 
Patient’s age, sex, and demographics were recorded, as were details of underlying 
disease including metastases. The prognostic tools/factors examined in the present 
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prospective study were those previously identified from a systematic review undertaken by 
our group. ).[6]  In brief, these prognostic tools/factors had been validated in adult patients 
with advanced cancer (n>100).  
Clinical markers: Clinician Predicted Survival (CPS) and ECOG-PS, the presence of 
metastases and weight loss (in the previous 3 months) were assessed by the treating clinician.  
The patient reported outcome measures (PROMs) dyspnoea, global health, cognitive 
impairment and anorexia were assessed by the patient using the European Organisation for 
the Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-
C30).[12]  
Bio-markers: CRP and albumin (combined in the mGPS), LDH, WCC, NC and LC.  
 
Statistical Analysis 
The primary outcome was to compare the prognostic value of the aforementioned 
factors. The secondary outcomes were to assess if such factors had independent prognostic 
value and could be combined to improve prediction of survival at one and three months from 
study entry.  These time points were chosen as clinically relevant for the management of 
patients with advanced cancer.[6, 13, 14] 
The primary outcome was to compare the prognostic value of the aforementioned 
factors on survival at one and three months using the area under the receiver operator curve 
method.  The sample size was based on a systematic review to identify key prognostic 
markers in patients with advanced cancer.[6] Based on this information a sample size of  
approximately 500 patients would have the power to reliably assess the prognostic value of 
approximately 10 variables.[15]  
The following were grouped according to specific thresholds.  The mGPS was 
grouped as: CRP <10 mg/L = 0,  CRP >10 mg/L = 1, CRP >10 mg/L and albumin < 35 g/L = 
2.[16]  Weight loss was grouped: <2.5%, 2.5-5.9%, 6-10.9%, 11-14.9, >15% according to 
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thresholds described by Martin et al.[17]  WCC, NC and LC were categorised as above or 
below/equal to normal limits.[18]  LDH was classified as abnormal if >250 U/L.[19] EORTC 
QLQ-C30 scores were calculated using scoring procedures as described by Aaronson et 
al.[12] EORTC QLQ-C30 scales were analyzed as discrete categories representing 
underlying continuous constructs and PROMs (symptoms and quality of life variables) were 
defined as being present if the score was greater than 50.[20] CPS was categorised into days 
[<14days], weeks [15-56 days] or months [>57 days]). For categorical variables with >2 
categories (e.g. mGPS, ECOG-PS, weight loss, CPS), these were treated as continuous 
variables in terms of Hazard Ratios in line with their proven prognostic value. 10  
 All patients were followed up until death or study censoring which was the date of the 
end of the study (3.7.15) and nine months after the last patient was recruited. The survival 
time was defined as the number of months from study entry until death, or censored if 
patients were alive at follow-up date.  Area under the receiver operating curve (AUC) was 
measured to assess survival at one and three months.  Univariate logistic regression was used 
to examine whether the prognostic factors were predictive of death at one month and three 
months post consent.  Multivariate survival analysis was done using a stepwise backward 
conditional procedure to derive a final model of prognostic factors that had a significant 
independent relationship with survival at one month and three months. Only variables with a 
univariate p<0.1 were considered in the model.  
 To examine the relationship between ECOG-PS, mGPS and quality of life a series of 
X2 tests for trend were used. Quality of life was calculated using the summary score of the 
EORTC QLQ-C30 with a maximum score of 100.[21]   
All statistical testing was done at the 5% significance level with 95% confidence 
intervals reported. In order to adjust for multiple comparisons in the present study a p value 
of <0.01 was considered significant. All analyses were performed using IBM SPSS Version 
23.0 (SPSS, Chicago, IL). Where appropriate, mean and standard deviations (SD) or median 
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and inter-quartile range (IQR) are reported. Patients who have missing survival time end 
point (i.e. last known date alive or date of death) are not included in the analyses.   
  The study design was developed in conjunction with lay members of the National 
Cancer Research Institute palliative care clinical studies development group, including cancer 
survivors.  
Results  
Between 24th January 2013 and 25th September 2014, 563 were screened with 539 
recruited and core data available on ECOG-PS available on 478 (88.7%). The 
clinicopathological characteristics of patients are shown in Table 1. The mean (SD) age was 
67.04 (12.08) years and 256 (54%) patients were female. The minimum and median (IQR) 
follow up for survivors was 0 days and 198 (137-273) days respectively. When study data 
collection stopped, 194 (41%) patients were alive.  The median (IQR) survival was 4.27 
(1.86-7.03) months. The most common cancer type was lung present in 177 (37%) patients 
and metastases were present in 377 (85%) patients.  
The relationship between clinical- and bio-markers and survival at one and three 
months, using the AUC is shown in Table 2. ECOG-PS and mGPS had the highest AUC for 
survival at one month: ECOG-PS 0.79 (95% CI, 0.73-0.85; p<0.001) and mGPS 0.73 (95% 
CI, 0.67-0.79; p<0.001).  ECOG-PS and mGPS had the highest AUC for survival at three 
months: ECOG-PS 0.79 (95% CI, 0.71-0.81; p<0.001) and mGPS 0.74 (95% CI, 0.70-0.79; 
p<0.001).   
The univariate and multivariate analysis of survival at one and three months is shown 
in Table 3. The following independently predicted death at one month: ECOG-PS (HR 2.15, 
95%CI 1.40-3.30, p<0.001), mGPS (HR 2.03, 95%CI 1.23-3.35, p=0.006), and NC (HR 3.18, 
95%CI 1.67-6.01), p<0.001). The following independently predicted death at three months: 
ECOG-PS (HR 1.91, 95%CI 1.47-2.49, p<0.001), mGPS (HR 1.77, 95%CI 1.36-2.31, 
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p<0.001), weight loss (HR, 1.15, 95%CI 1.03-1.29, p=0.013), LDH (HR 2.00, 95%CI 1.15-
3.47, p=0.013) and WCC (HR 2.50, 95%CI 1.71-3.66, p<0.001).   
The percentage survival (SE) at one and three months as per the factors which are the 
strongest predictors of survival on multivariate analysis, is shown in Table 4. To illustrate, 
survival at one month ranges from 98(1)% ECOG-PS1 to 25(11)% ECOG-PS 4.  It is of note 
that the factors with the greatest discrimination in survival at one and three months are 
ECOG-PS and the mGPS.  
The relationship between ECOG-PS, mGPS and quality of life was also examined 
(data not shown). Decreasing PS and increasing inflammation were independently associated 
with deteriorating quality of life. In combination mean quality of life scores ranged from 80 
(ECOG-PS1, mGPS 0) to 46 (ECOG-PS3, mGPS 2) p<0.001; the combination providing a 
greater differentiation of quality of life scores than each component in isolation (ECOG-PS or 
mGPS) in isolation.  
 
Discussion  
 A number of clinical and bio-markers predict survival one and three month survival in 
patients with advanced cancer.  The present study compares these prospectively and shows 
the superior prognostic value of several key prognostic factors including performance status 
and biomarkers of the inflammatory response (e.g. mGPS). It is of interest that markers of the 
inflammatory response compare favourably to performance status in terms of survival 
prediction. In the present study the prognostic value of ECOG-PS and mGPS was retained 
when adjusted for age, sex and cancer location. Given that both ECOG-PS and mGPS have 
been extensively validated in both observational and randomised clinical trial settings it is 
likely that this prognostic framework will be clinically useful in the majority of common 
solid tumours. Further, ECOG-PS and mGPS predicts survival but are also related to overall 
quality of life.  
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The results of the present study should reassure clinicians of the value of performance 
status in prognostication. However the findings should also alert clinicians that patients who 
have a good performance status and systemic inflammation are at increased risk of poorer 
quality of life and survival. but also have a higher symptom burden. The ECOG-PS/mGPS 
framework reported herein has been validated previously by our group and could be used to 
stratify patients who may benefit from referral to palliative care services.[11, 13]  
The present study advances the research agenda in the area of prognostication. In 
patients with advanced cancer, the decision is often not “can we treat with anti-cancer 
therapy?” rather “should we treat with anti-cancer therapy?”, and accurate assessment of 
prognosis is a key consideration in this regard. Using robust prognostic factors (e.g. 
biomarkers of the inflammatory response) in combination with clinical judgement, may help 
inform decisions regarding appropriate place for end of life care (e.g. hospice admission), 
while the latter may inform the decision to continue with anti-cancer therapy (e.g. 
radiotherapy for painful bone metastases) or clinical trial participation.  
To our knowledge, this is the first report to prospectively compare validated 
prognostic factors for use in patients with advanced cancer. It was of interest that a number of 
validated prognostic factors did not, on multivariate analysis, retain independent prognostic 
value at one and three months.  For example weight loss was less prominent as an 
independent prognostic factor than might be anticipated from the literature pertaining to the 
cachexia associated with cancer.  Indeed, the prominence of weight loss as the cornerstone of 
palliation in patients with advanced cancer has been questioned.[22-24]  Further, PROMs 
often associated with reduced survival (dyspnoea, global health, cognitive impairment and 
anorexia) were less prominent suggesting that their prognostic value is dependent at least in 
part,  on physical function and the systemic inflammatory response.  Indeed, significant 
associations have been reported between such PROMs, physical function and systemic 
inflammation in large independent cohorts.[8, 11]  If this were to be the case, then 
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improvement in physical function[25]  and moderation of the systemic inflammatory 
response[26] should result in an improvement of such PROMs. 
This would be in keeping with observations that the systemic inflammatory response 
has prognostic value in non-malignant conditions with recent work supporting the 
inflammatory hypothesis of atherosclerosis.[27] Although in cancer the use of anti-
inflammatory therapies in a tumouricidal role is increasing, the sound argument of targeting 
the inflammatory response to influence survival in cancer, has by in large been neglected. 
The results from the present study support the hypothesis that the inflammatory response is a 
key driving factor in survival in cancer and the need for an increased recognition its 
importance as a  therapeutic target for palliation in patients with advanced cancer.[11, 28] 
Recently, a number of groups have carried out a prospective comparison of validated 
prognostic factors in patients in the palliative care setting.  For example, Baba and co-
workers reported, in approximately 2,500 patients in a multicentre study in variety of 
palliative care settings, the feasibility and accuracy of the PaP score, D-PaP score, PPI and 
modified PiPS model, including patients receiving chemotherapy.[7] The most important 
finding was that all prediction tools investigated in the study, PaP score, D-PaP score, PPI 
and modified PiPS model, can differentiate subgroups with different survival profiles in all 
palliative care settings.  Similarly, Hui and co-workers reported, in approximately 200 
patients with advanced cancer, that PaP-score was more accurate than CPS, and the addition 
of CPS to the prognostic model reduced its accuracy.[29]  
Therefore, it is clear that the prognostic models PPI and PaP have indeed reliable 
prognostic value.  However, these prognostic models include ECOG-PS and the PaP also 
includes CPS.  Indeed, the prognostic value of these models depend largely on the assessment 
of functional status as a core component and ECOG-PS, compared with the sparse use of PPI 
and PaP tools, is used extensively in routine clinical practice.[6] (Simmons et al., 2017).  
Therefore, in addition to ECOG-PS, a number of core prognostic variables that were 
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identified in a recent systematic review, including the mGPS, were included in the present 
analysis.[6] This approach has the advantage of identifying core prognostic variables that add 
substantially to ECOG-PS and thereby simplifying the patient assessment. 
In the present study after ECOG-PS and mGPS, CPS was the third and fourth most 
significant factor predicting death at one- and three months, respectively.  Although due to its 
subjective nature CPS is often reported as being inaccurate, the present results confirm the 
clinical utility of the CPS.  In the context of the integration of palliative care and oncology 
the combination of CPS and either ECOG-PS or mGPS was not examined in the present 
study 
The primary outcome was a direct comparison of variables previously identified to 
have prognostic value in patients with advanced cancer.  It was clear from the present 
analysis that a number of prognostic variables had AUC with overlapping 95% CI.  This 
perhaps not surprising since for example performance status is a key component of the CPS 
and a number of prognostic tools in patients with advanced cancer.[6] With the increasing 
integration of oncology and palliative care [30] it is likely that performance status will 
increasingly form the cornerstone of outcome prediction. 
Limitations 
The present study had a number of limitations.  As the majority of patients were under 
the care of palliative care services, it may be assumed they had a high symptom burden, 
which itself may be an indicator of a shorter prognosis. Further, although recruitment was 
across 16 centres, the present cohort may not be entirely representative, but was well defined 
in terms of the components of validated prognostic scores.  This will allow comparison with 
other populations in future studies. Another limitation was that not all reported prognostic 
factors were evaluated. However, the choice of factors was based on a rigorous systematic 
review and only those which were assessed in populations greater than 100, and examined 
and validated in two or more independent data sets, were included.  Another limitation is that 
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the recruitment/sampling strategy was opportunistic however the heterogeneity of the primary 
cancer types herein would support the findings in multiple tumour types. Patients with 
delirium based on clinical assessment were not included in the present study.  However, 
formal screening for delirium was not carried out as part of eligibility assessment and it is 
possible that patients with hypoactive delirium were not identified and therefore may have 
been recruited as part of the study. In the present study the EORTC-QLQ-30 was used to 
assess symptoms and cognitive impairment.  Although this has been used and validated 
extensively there are now more targeted and sensitive tools available.  Further studies are 
required to examine whether such tools enhance the ECOG-PS/ mGPS framework.  
Another limitation of the present study is that some of the variables studied (e.g. 
symptoms) were dichotomised based on 50% since the ideal cut-off was not clear from the 
literature.  This was a pragmatic approach to examine whether the variable had prognostic 
value. 
The median survival of the studied population was 4 months and therefore the 
efficacy of the ECOG-PS/mGPS framework may not be useful in other cohorts of patients 
with advanced care that have a different survival profile.  However, given the simplicity and 
objective nature of the framework it is likely that it will tested extensively in different patient 
cohorts.[31] 
Clearly assessment of performance status is subjective, however this is probably in 
keeping with day-to-day clinical practice.  Although it is widely recognised that ECOG-PS is 
a subjective measure and has questionable inter-rater reliability, the value of PS as a key 
prognostic marker in advanced cancer is well recognised.[32] 
 
Conclusion 
In the first prospective comparison of validated prognostic factors, most factors 
predicted survival; however the superior value of performance status and biomarkers of the 
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inflammatory response (mGPS, neutrophil count) were demonstrated. Moreover, combining 
clinical factors with biomarkers (e.g. performance status with the mGPS) has been reported to 
have a differential impact on quality of life.[11, 13] This framework should alert clinicians to 
patients who are at increased risk of dying, but may also have a higher symptom burden.  
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Table 1.  Clinicopathological characteristics of patients with advanced cancer (n=478) 
 Parameter n (%) 
 Age (<65, 65-74, >74) 191(40), 140(29), 147(31) 
 Female  256 (54) 
Place of care 
  Home 341(71) 
  Hospital 30 (6) 
  Specialist Palliative Care Unit 93 (19) 
  Other 14 (3) 
Primary Cancer  
  Neurological 8 (2) 
  Lung 177 (37) 
  Gastrointestinal 141 (29) 
  Urological 24 (5) 
  Gynaecological 24 (5) 
  Melanoma 28 (6) 
  Haematological 10 (2) 
  Breast 50 (11) 
  Unknown Primary 8 (2) 
  Other 8 (2) 
Previous Anti-cancer therapy  
  Chemotherapy  281/478 (59) 
  Radiotherapy 187/478 (39) 
  Hormonal  42/478 (9) 
Clinician Predicted Survival (n=463) 
    Days   8/463 (2) 
    Weeks  87/463 (19) 
    Months  368/463 (79) 
Performance Status (ECOG) 
1, 2, 3, 4  189(39), 201(42), 72(15), 16(3) 
mGPS 
0, 1, 2  178 (37), 99(21), 201(42) 
Patient Reported Outcome Measures [EORTC score, median (IQR)] 
Dyspnoea present   139/461 (30); [33 (0-67)] 
Global Health impaired  217/459 (47); [83 (50-100)] 
Cognitive impairment   331/461 (72); [83 (50-100)] 
Anorexia   159/461 (34); [33 (0-67)] 
Metastases present  377/446 (85) 
Weight loss last 3 months (%) (n=462) 
<2.5, 2.5-5.9, 6-10.9,11-14.9, >15  272(59),31(7),60(13),42(9),57(12) 
Biomarkers [median (IQR)] 
Elevated LDH (>250 U/L)  335/446 (75%); [394 (251-557)] 
Elevated White Cell Count (>11 x109/L)  124/470 (26%); [7.7 (5.6-11.4)] 
Elevated Neutrophil Count >7.5 x 109/L  148/469 (32%); [5.2 (3.5-8.8)] 
Elevated Lymphocyte Count 3.0 x109/L 
 
 20/469 (4%); [1.2 (0.8-1.70)] 
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Table 2 - The relationship between prognostic factors and survival (one month and three months) in patients with advanced cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
AUC-  Area under the Receiver Operating Curve  
 
 
 
 
 Death at one month Death at 3 months 
  % AUC (95% CI) P  % AUC (95% CI) P 
  Age (<65/65-74/>74) 13/13/18 0.57 (0.49-0.66)  0.044  28/39/37  0.56 (0.50-0.62) 0.048 
  Sex (male/ female)   16/13   0.47 (0.38-0.55)  0.044  39/31  0.44 (0.40-0.50) 0.054 
Clinician Predicted Survival 
    Months/Weeks/Days    8/37/100   0.71 (0.63-0.79)  <0.001  25/72/100  0.68 (0.62 -0.73) <0.001 
Performance Status (ECOG) 
    1/2/3/4   2/13/38/75   0.79 (0.73-0.85)  <0.001  13/37/71/94  0.79 (0.71- 0.81) <0.001 
  Patient Reported Outcome Measures 
    Dyspnoea (N/Y) 10/22 0.61 (0.53-0.69)  0.005  26/49  0.61 (0.56-0.67) <0.001 
    Global Health (Y/N) 8/19 0.61 (0.54-0.69)  0.005  24/43  0.61 (0.55-0.66) <0.001 
    Cognitive Impairment (N/Y) 21/10 0.41 (0.33-0.49)  0.019  42/29  0.44 (0.38-0.49) 0.03 
    Anorexia (N/Y) 10/20 0.59 (0.52-0.68)  0.014  26/46  0.60 (0.54-0.66) 0.001 
  Metastases (N/Y)   10/15   0.55 (0.46-0.63)  0.041  33/36  0.51 (0.45-0.57) 0.78 
  Weight loss last 3 months (%) 
    <2.5/2.5-5.9/6-10.9/11-14.9/>15   13/3/10/7/32   0.56 (0.47-0.66) 0.14  
28/23/37/45/
56 
 0.62 (0.55-0.67) <0.001 
Biomarkers 
    mGPS 0/1/2   2/14/26   0.73 (0.67-0.79)  <0.001  9/38/55  0.74 (0.70-0.79) <0.001 
  LDH <=250/>250 U/L 5/18 0.59 (0.51-0.66)  0.039  15/40  0.61 (0.55-0.66) 0.001 
  White Cell Count <=11/>11 x109/L 7/33 0.68 (0.60-0.77)  <0.001  24/60  0.64 (0.58-0.70) <0.001 
  Neutrophil Count <=7.5/ >7.5 x 
109/L 
7/29 0.72 (0.64-0.80)  <0.001  23/57  0.67 (0.61-0.73) <0.001 
  Lymphocyte Count <=3.0/>3.0 
x109/L 
14/10 0.49 (0.40-0.57)  0.76  35/15  0.48 (0.42-0.54) 0.51 
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 Table 3.  The relationship between prognostic factors and survival (one and three months) in patients with advanced cancer: univariate and 
multivariate analysis. 
Prognostic factors in bold used in multivariate analysis.
 Death at one month Death at three months 
   Univariate Multivariate Univariate Multivariate 
    HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Age (<65/65-74/>74) 1.23 (0.92-1.63) 0.158   1.19 (1.00-1.43) 0.056   
Sex (male/ female) 0.78 (0.49-1.26) 0.309   0.76 (0.56-1.04) 0.084 0.59 (0.41-0.86) 0.006 
Clinician Predicted Survival 
    Months/Weeks/Days  0.85 (0.78-0.90) <0.001    0.80 (0.74-0.85) <0.001 0.35 (0.01-0.58) 0.047 
Performance Status (ECOG) 
    1/2/3/4 3.71 (2.84 -
4.85) 
<0.001 2.15 (1.40-3.30)  <0.001 2.90 (2.42-3.47) <0.001 1.96 (1.50 -257) <0.001 
  Patient Reported Outcome Measures 
    Dyspnoea (N/Y) 2.32 (1.41-3.82)  0.001   2.26 (1.64-3.11) <0.001   
    Global Health (Y/N 0.60 (0.31-0.73)  0.001   0.54 (0.36-0.67) <0.001   
    Cognitive Impairment (N/Y) 0.45 (0.27-0.75)  0.002   0.61 (0.44-0.85) 0.003   
    Anorexia (N/Y) 2.21 (1.34-3.63)  0.002   2.09 (1.52-2.88) <0.001   
  Metastases (N/Y) 1.57 (0.72-3.45)  0.379   1.14 (0.73-1.77) 0.564   
  Weight loss last 3 months (%) 
     <2.5/2.5-5.9/6-10.9/11-14.9/>15 1.21(1.04-1.41)  0.017    1.26 (1.14-1.39) <0.001 1.16 (1.03-1.30) 0.012 
Biomarkers 
    mGPS 0/1/2 3.15 (2.13-4.65) <0.001 2.03 (1.23-3.35)   0.006 2.57 (2.08-3.19) <0.001 1.79 (1.37-2.33) <0.001 
 LDH <=250/>250 U/L 3.50 (1.51-8.11)  0.003   3.09 (1.86-5.11) <0.001 2.30 (1.32-4.01) 0.003 
 White Cell Count <=11/>11 x109/L 5.53 (3.24-8.76) <0.001   3.54 (2.59-4.84) <0.001   
Neutrophil Count <=7.5/ >7.5 x 109/L 5.23 (3.12-8.56) <0.001 3.18 (1.67-6.01)  <0.001 3.45 (2.52-4.72) <0.001 2.67 (1.83-3.93) <0.001 
Lymphocyte Count <=3.0/>3.0 x109/L 0.71 (0.18-2.88) 0.627   0.39 (0.13-1.29) 0.111   
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Table 4 – Percentage Survival (SE) at one and three months as per Clinician Predicted Survival, ECOG-
Performance Status, modified Glasgow Prognostic Score, Lactate Dehydrogenase and Neutrophil Count 
categories.  
  Survival 
  One month Three months 
Clinician Predicted Survival  
(n=463) 
Days   
n=8 
 
n=8 
Weeks  63 (5) 
n=87 
29 (5) 
n=87 
Months 92 (1) 
n=368 
76 (2) 
n=368 
ECOG-Performance Status  
(n=478) 
1 98 (1) 
n=189 
87 (2) 
n=189 
2 88 (2) 
n=201 
64 (3) 
n=201 
3 63 (6)  
n=72 
30 (5) 
n=72 
4 25 (11) 
n=16 
6 (6) 
n=16 
modified Glasgow Prognostic Score 
(n=478) 
0 98 (1) 
n=178 
91 (2) 
n=178 
1 87 (3) 
n=99 
62 (5) 
n=99 
2 74 (3) 
n=201 
46 (4) 
n=201 
Lactate Dehydrogenase (U/L) 
(n=446) 
<=250 95 (2) 
n=111 
86 (3) 
n=111 
>250 U/L 83 (2) 
n=335 
61 (3) 
n=335 
Neutrophil Count (n=469) 
(n=469) 
<=7.5 x 109/L 94 (1) 
n=321 
93 (1) 
n=321 
>7.5 x 109/L 70 (4) 
n=148 
70 (4) 
n=148 
 
  Where n<10, data not reported. SE= standard error.  
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